IDNA

iShares Genomics Immunology and Healthcare ETF

$26.11
+0.00%
Market closed. Last update: 12:39 PM ET

📎 Investment Objective

The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the investment results of an index composed of companies that could benefit from the development and commercialization of genomics and immune therapy.

Overview

ETF tracking iShares Genomics Immunology and Healthcare ETF

Category Healthcare
Issuer BlackRock
Inception Date 2019-06-13
Market Cap $130.6M
Average Volume N/A
Dividend Yield 1.01%
52-Week Range $17.92 - $26.29
VWAP $26.13

Performance

Loading performance data...

Price Chart

Investment Summary

📎 Investment Objective

The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the investment results of an index composed of companies that could benefit from the development and commercialization of genomics and immune therapy.

🎯 Investment Strategy

The ETF employs a passive management (or index-tracking) strategy designed to track the performance of the NYSE FactSet Global Genomics and Immunology Index. The fund generally invests at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index.

✨ Key Features

  • Provides exposure to companies involved in genomics, immunology, and other healthcare-related technologies
  • Passively managed to track the NYSE FactSet Global Genomics and Immunology Index
  • Low expense ratio of 0.00%
  • Relatively new fund with limited performance history

⚠️ Primary Risks

  • Concentration risk as the fund is focused on a specific sector (healthcare/biotech)
  • Volatility risk as the fund may experience significant price swings due to the speculative nature of the underlying companies
  • Lack of diversification outside of the healthcare/biotech sector
  • Liquidity risk due to the fund's small asset size and trading volume

👤 Best For

This ETF may be suitable for investors with a long-term investment horizon and a higher risk tolerance who are seeking exposure to the genomics, immunology, and broader healthcare technology sectors. It may be appropriate as a satellite holding in a diversified portfolio, rather than as a core investment.